Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Longeveron Inc.LGVN · Entity 7608 | Chief Executive Officer | October 01, 2026 | October 05, 2026 |
| NRX Pharmaceuticals, Inc.NRXP · Entity 6523 | Director · CHIEF EXECUTIVE OFFICER | December 16, 2022 | December 19, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Longeveron Inc.
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 74,916 |
Reported balance
After 2026-10-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-10-01 · Tax withholding · Disposed 1,987 · Balance 74,916 F1: Shares withheld to satisfy tax obligations in connection with the vesting of a restricted stock unit (RSU) award. F2: Includes RSUs subject to future vesting. F3: Amounts reflect the one-for-ten reverse stock split undertaken by Issuer in August 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld to satisfy tax obligations in connection with the vesting of a restricted stock unit (RSU) award.
F2: Includes RSUs subject to future vesting.
F3: Amounts reflect the one-for-ten reverse stock split undertaken by Issuer in August 2026.
NRX Pharmaceuticals, Inc.
Report date December 16, 2022 · Filed December 19, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | Direct | 50,000 |
Reported balance
After 2022-12-16 transaction · row 1
1 source rowRow 1 · 2022-12-16 · Purchase · Acquired 50,000 · Balance 50,000 F1: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.09 to $1.20. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.09 to $1.20. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 5, 2026 22:00 UTC | Longeveron Inc. LGVN · Entity 7608 | Tax withholdingClass A Common Stock | 1,987 | $2.59 | $5,146.33 |
DisclosureSEC source: 0001214659-26-012569 · marketforms-74103.xml · nonDerivative · entry 1 Willard Stephen H · CIK 0001325232 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,916 F1 · shares: Shares withheld to satisfy tax obligations in connection with the vesting of a restricted stock unit (RSU) award. F2 · balance_after: Includes RSUs subject to future vesting. F3 · balance_after: Amounts reflect the one-for-ten reverse stock split undertaken by Issuer in August 2026. Read SEC document |
| July 01, 2026 Filed Jul 7, 2026 00:55 UTC | Longeveron Inc. LGVN · Entity 7608 | Tax withholdingClass A Common Stock | 18,046 | $0.73 | $13,157.34 |
DisclosureSEC source: 0001214659-26-008254 · marketforms-73589.xml · nonDerivative · entry 1 Willard Stephen H · CIK 0001325232 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 771,681 F1 · shares: Shares withheld to satisfy tax obligations in connection with the vesting of a restricted stock unit (RSU) award. F2 · balance_after: Includes RSUs subject to future vesting. Read SEC document |
| May 01, 2026 Filed May 5, 2026 22:00 UTC | Longeveron Inc. LGVN · Entity 7608 | GrantClass A Common Stock | 500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-26-005620 · marketforms-73063.xml · nonDerivative · entry 1 Willard Stephen H · CIK 0001325232 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 789,727 F1 · shares: Represents the award of time-based vesting Restricted Stock Units (RSUs). F2 · balance_after: Includes RSUs subject to future vesting. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 21:00 UTC | Longeveron Inc. LGVN · Entity 7608 | Tax withholdingClass A Common Stock | 4,740 | $1.12 | $5,308.80 |
DisclosureSEC source: 0001214659-26-004337 · marketforms-72890.xml · nonDerivative · entry 1 Willard Stephen H · CIK 0001325232 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 289,727 F1 · shares: Shares withheld to satisfy tax obligations in connection with the vesting of a restricted stock unit (RSU) award. F2 · balance_after: Includes RSUs subject to future vesting. Read SEC document |
| March 02, 2026 Filed Mar 14, 2026 00:59 UTC | Longeveron Inc. LGVN · Entity 7608 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0001214659-26-003290 · marketforms-72514.xml · derivative · entry 4 Willard Stephen H · CIK 0001325232 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Class A Common Stock · 200,000 shares Expires 2036-03-02 F5 · derivative.exercise_date: The option vests quarterly over a four-year period beginning on April 1, 2026. Read SEC document |
| March 02, 2026 Filed Mar 14, 2026 00:59 UTC | Longeveron Inc. LGVN · Entity 7608 | GrantClass A Common Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-26-003290 · marketforms-72514.xml · nonDerivative · entry 3 Willard Stephen H · CIK 0001325232 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 294,467 F3 · shares: Represents the award of time-based vesting Restricted Stock Units (RSUs). F4 · balance_after: Includes RSUs subject to future vesting. Read SEC document |
| March 02, 2026 Filed Mar 14, 2026 00:59 UTC | Longeveron Inc. LGVN · Entity 7608 | Tax withholdingClass A Common Stock | 105,533 | $0.55 | $57,515.49 |
DisclosureSEC source: 0001214659-26-003290 · marketforms-72514.xml · nonDerivative · entry 2 Willard Stephen H · CIK 0001325232 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,467 F2 · shares: Shares withheld to satisfy the tax obligations in connection with the initial hire award of Class A Common Stock. Read SEC document |
| March 02, 2026 Filed Mar 14, 2026 00:59 UTC | Longeveron Inc. LGVN · Entity 7608 | GrantClass A Common Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-26-003290 · marketforms-72514.xml · nonDerivative · entry 1 Willard Stephen H · CIK 0001325232 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 F1 · shares: Represents the initial hire award of Class A Common Stock. Read SEC document |
| December 16, 2022 Filed Dec 19, 2022 12:14 UTC | NRX Pharmaceuticals, Inc. NRXP · Entity 6523 | PurchaseCommon Stock, par value $0.001 per share | 50,000 | $1.17 | $58,500.00 |
DisclosureSEC source: 0001415889-22-012654 · form4-12192022_121215.xml · nonDerivative · entry 1 Willard Stephen H · CIK 0001325232 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.09 to $1.20. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.